key: cord-1002595-1jeh7hke
authors: Yin, Shengxia; Tong, Xin; Huang, Aijun; Shen, Han; Li, Yang; Liu, Yong; Wu, Chao; Huang, Rui; Chen, Yuxin
title: Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient
date: 2020-07-02
journal: J Infect
DOI: 10.1016/j.jinf.2020.06.076
sha: 3a326f8f94043a8a1422b6b1ee1944aea049fbaa
doc_id: 1002595
cord_uid: 1jeh7hke

We followed–up a mild COVID-19 patient for 91 days and serially monitored his serum antibodies to four SARS-CoV-2 related antigens (NP, RBD, S1 and ECD) and neutralization activities. Our data revealed a profile of serial antibody responses during the progress and a quick decline of neutralization activities after discharge.

We followed-up a mild COVID-19 patient for 91 days and serially monitored his serum antibodies to four SARS-CoV-2 related antigens (NP, RBD, S1

and ECD) and neutralization activities. Our data revealed a profile of serial antibody responses during the progress and a quick decline of neutralization activities after discharge.

Since December 2019, an outbreak of 2019 novel coronavirus disease causing a severe pneumonia has been spreading globally (1) . The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was revealed to be the causative agent (2) . Though, recent studies demonstrated that transfusion of convalescent plasma containing the neutralizing antibody responses resulted in clinical improvement (3) . The isotype, specificity and duration of protective antibodies in recovered COVID-19 patients were still not well-known. Antiviral treatment, infection control, epidemiological measures, and vaccination against SARS-CoV-2 were in urgent demand of reliable data for profiles of serial serum antibody responses during the progress of COVID-19. Here we retrospective studied a longitudinal profile of anti-SARS-CoV-2 antibody responses in a COVID-19 patient with mild clinical presentation. We serially monitored the IgA, IgM, IgG and IgG isotypes including IgG1 to IgG4 responses specific to four SARS-CoV-2 related antigens, including nucleocapsid protein (NP) and receptor binding domain (RBD), S1

protein, and ectodomain of spike protein (ECD)(4) , from the 4th day he was symptom onset till the 91st day after symptom onset.

On February 1, 2020, a 27-year-old man sought medical advice for a fever of 38°C and cough. Upon admission, his chest computed tomography (CT) scans showed focal ground-glass opacities and nasopharyngeal swab test was positive for SARS-CoV-2 by real-time reverse transcription-PCR (RT-PCR). He was diagnosed as mild symptomatic patients and admitted to the hospital. The RT-PCR tests for SARS-CoV-2 were positive for two days and symptoms were resolved except for mild cough in the next following days. For all RT-PCR results were negative since February 4, he was discharged on February 22. And we followed him up till the 91st day after symptom onset. The clinical course was summaried ( Figure 1A ).

Using four recombinant SARS-CoV-2 antigens, serial specific IgA, IgM, IgG and IgG isotypes including IgG1 to IgG4 responses were analyzed by an indirect enzyme-linked immunosorbent assay (ELISA) ( Figure 1B ). Of note, the level of anti-SARS-CoV-2 IgG2 and IgG4 were almost undetectable. IgG specified to all the four antigens were peaked at 27 days after symptoms onset and decreased gradually until the 91 days after symptoms onset. Correlatively, IgG1 specified to ECD, S1 and RBD were peaked at 7 days and specified to NP was peaked at 14 days after symptoms onset. And IgG1 specified to all the four antigens stayed at relative high level till the 91st day. Though IgG3 responses to ECD, S1 and NP were increased since the 4th day and mildly declined until the 91st day, responses especially to RBD was almost undetectable on the 91st day. IgA reacted to ECD and RBD were increased from the 4th day and stayed sustainably at high level until the 91st day. On the contrary, NP and S1 specified IgA dropped rapidly after the peak point and was undetectable at 91st day after the symptoms onset. In addition, NP reacted IgM sharply decreased from 7th day till17th day and stayed undetectable.

The neutralization activities were further determined by the pseudovirus microneutralization assay. The activity was rapidly increased from the 4 th day to the 20 th day after the symptoms onset, peaked with a titer of 2954 (ID 50 ), and decreased obviously then. On the 91th day the titer was 114 (ID 50 ), only 4% of the peak point ( Figure 1C ).

Our case highlighted that the SARS-CoV-2 specific humoral immunity is critical during clinical recovery of COVID-19. Of note, antibody specific to RBD which is responsible for binding to angiotensin-converting enzyme 2 (ACE2) was correlated with neutralizing capability (5, 6) . Early presence of anti-RBD antibody might facilitate virus clearance, contributing to a transient positive viral detection. The level of RBD-specific antibody might be associated with the favorable outcome of COVID-19 (7) . Secondly, high magnitude of antibody responses targeting at spike protein RBD region was identified, suggesting that RBD region is highly immunogenic, an ideal antigen candidate for vaccine design. Thirdly, our data suggested a rapidly 

A Novel Coronavirus from Patients with Pneumonia in China

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. The New England journal of medicine

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. The Lancet Infectious Diseases

Characterization of anti-MERS-CoV antibodies against various recombinant structural antigens of MERS-CoV in an imported case in China. Emerging microbes & infections

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series